Breaking News: Halozyme’s Enhanze Technology Receives Approval for Roche’s Subcutaneous Tecentriq in Great Britain
Tecentriq® Subcutaneous Formulation with ENHANZE®: Revolutionizing Cancer Immunotherapy Introduction In a groundbreaking development, the first subcutaneous anti-PD-(L)1 cancer immunotherapy is now available to patients in Great Britain. Roche’s Tecentriq® SC (atezolizumab) delivers a game-changing treatment option for cancer patients, thanks to Halozyme Therapeutics, Inc.’s ENHANZE® drug delivery technology. This innovation not only enhances the efficacy…